当前位置: X-MOL 学术J. Diabetes Investig. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-03-25 , DOI: 10.1111/jdi.13237
Baodi Xing 1 , Yuhang Zhao 1 , Bingzi Dong 1 , Yue Zhou 1 , Wenshan Lv 1 , Wenjuan Zhao 1
Affiliation  

Non‐alcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus. Currently, some studies have found that sodium–glucose cotransporter 2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve non‐alcoholic fatty liver in addition to its hypoglycemic effect. Thus, we undertook a meta‐analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors on the treatment of NAFLD.

中文翻译:


钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者非酒精性脂肪肝的影响:随机对照试验的荟萃分析。



非酒精性脂肪肝(NAFLD)在 2 型糖尿病患者中越来越常见。目前,一些研究发现钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂作为一种新型降糖药物,除了具有降血糖作用外,还可以改善非酒精性脂肪肝。因此,我们对随机对照试验进行了荟萃分析,以评估 SGLT2 抑制剂治疗 NAFLD 的疗效。
更新日期:2020-03-25
down
wechat
bug